Literature DB >> 8928363

[Risk-guided after-care of testicular tumor].

K H Schölermann1, R Dettmann, M Hartmann.   

Abstract

Results in 503 patients with germ cell testicular tumors treated between 1982 and 1992 were analyzed. A follow-up program for germ cell tumors is presented which is related to the individual risk of tumor relapse. The overall relapse rate was 7%, of which 82% had recurrent tumor within 1 year after treatment. A low risk of relapse (3-5%) is seen in patients with seminoma stage I and radiation and, usually, in early-stage patients treated with polychemotherapy. A moderate risk of relapse (6-11%) is observed in patients with non-seminoma stage I and lymphadenectomy without chemotherapy. Seminoma without radiation and non-seminoma without lymphadenectomy in clinical stage I, non-seminoma stage IIa and IIb without adjuvant chemotherapy after lymphadenectomy, and primary high tumor mass present a high risk of relapse (> 11%). Tumor recurrence is localized mainly in lung and retroperitoneum. Most important in the follow-up are tumor marker and chest X-ray. During the first year examinations should take place every 3 months in the low-risk group and every 2 months in the moderate and high risk group. Computer tomography is only required in high-risk patients. Usually a 3-year follow-up is sufficient.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8928363

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  3 in total

Review 1.  [Therapeutical options for seminomas at clinical stage I-IIA/B].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

Review 2.  [Follow-up of testicular germ cell tumors-historical aspects and current recommendations].

Authors:  Klaus-Peter Dieckmann; Christian Guido Ruf; Raphael Gübitz; Christian Wülfing; Friedemann Zengerling
Journal:  Urologe A       Date:  2022-04-06       Impact factor: 0.639

Review 3.  [Aftercare in testicular cancer is worthwhile. Recurrences are curable].

Authors:  T S Pottek; K-P Dieckmann
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.